Overview
MREO market data
Price History
MREO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.05 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.20 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -8,375.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.20 – $2.37 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $47.3M · P/B 8.91.
Company News
12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga · Aug 11, 2026, 9:06 PM
12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga · Aug 11, 2026, 5:06 PM
8-K filing — Mereo BioPharma Group plc (MREO)SEC EDGAR · Aug 11, 2026, 12:26 PM
Mereo BioPharma Group Q2 EPS $(0.01), InlineBenzinga · Aug 11, 2026, 12:17 PM
Mereo BioPharma Group shares are trading higher after the company announced an optional and license agreement with Zydus Unit Sentynl For U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.Benzinga · Aug 11, 2026, 12:09 PM
Mereo BioPharma Announces Option And License Agreement With Zydus Unit Sentynl For US Rights To Alvelestat In AATD-LD; Eligible For $40M Upfront On Option Exercise, Up To $435M In MilestonesBenzinga · Aug 11, 2026, 12:05 PM